NR3C1 and ovarian carcinoma: Glucocorticoid receptor (GR) ligand, Relacorilant in combination with Nab-paclitaxel improved outcomes with limited toxicity in patients with adenocarcinoma and ovarian cancer (Munster et al., 2019).